Key takeaways from Wall Street analysts this week.
Here are the key takeaways from Wall Street analysts this week.
Healthpeak Properties
What happened? On Monday, Raymond James upgraded Healthpeak Properties Inc. to Outperform with a $20 price target and downgraded Healthcare Realty Trust Incorporated to Market Performance.
Quick Take: RayJa upgrades DOC, downgrades HR. DOC is undervalued, HR is overvalued.
Full Story: RayJa changes its view on DOC and HR, upgrading DOC to Outperform and downgrading HR to Underperform. RayJa's analysts adjusted DOC's earnings forecast, expecting lower NOI growth in the life sciences space, but this is closer to market sentiment. Meanwhile, HR remains unchanged. DOC is gaining recognition because it's been an ugly duckling recently, down 15%, while its peers HR and ARE are showing strong growth. Sure, occupancy in the life sciences space is plummeting, but RayJa believes it will soon bottom out—unless biotech IPOs continue to pop up, as they did last week. DOC is trading at a bargain price with an attractive 6.7% dividend yield, and everyone is undervaluing it. The key is for life sciences fundamentals not to deteriorate further, or RayJa's optimistic outlook could fade.
HR, on the other hand, became overconfident after its new strategic plan impressed the public, outperforming DOC by 18%. But now it's trading at full net asset value, and everyone is betting big on it. RayJa doesn't buy it—HR's plan to increase NOI margins by 200 basis points will take forever, and those $1 billion in diluted sales could drag on until 2026, negatively impacting 2027 revenue. Unless HR pulls a rabbit out of a hat or starts selling assets like hotcakes, RayJa doesn't believe in what they're proposing.
TransMedics Group
What happened? On Tuesday, Evercore initiated coverage on TransMedics Group Inc. with an Outperform rating and a $155 price target.
Quick Takeaway: Evercore supports OCS+NOP despite the valuation. Seeks growth and high margins by 2028.
Full Story: Evercore strongly supports OCS+NOP, arguing that it's worth the steep price of $100,000-$120,000 per procedure. Of course, this is more expensive than DCD organs at $75,000-$110,000, but Evercore is confident of better patient outcomes and smoother operations—fewer vendor, logistics, and scheduling issues.
The brokerage is betting heavily on reaching 10,000 transplants and generating over $1 billion in revenue by 2028, with liver transplantation leading the way, accounting for 50% of the market. Heart and lung transplantation should ramp up after trials in 2026, and after that, OCS Kidney and the global market will be the next big areas. Evercore also expects attractive operating margins of 30% by 2028, up from mid-10s in 2025, thanks to streamlining general and administrative expenses. But don't rush – Evercore's target price is a hefty 44x 2026 P/E or 8.5x 2026 EV/Sales, falling to 21x 2028 P/E. The main risks? Failure in next-generation heart/lung trials, increased competition in the liver segment, or deterioration in operating leverage.
Progressive
What happened? On Wednesday, BMO Capital downgraded Progressive Corp to "Market Perform" with a $250 price target.
Quick Take: PGR growth is slowing, revenue revisions are negative. GEICO is recovering, threatening PGR's dominance.
Full Story: BMO says PGR's outperformance could boost bottom line, but the bank is more concerned about revenue revisions, which are tracking negative (~2%). Competitive pressure is mounting as GEICO increases advertising spending, and industry-leading double-digit PGR growth is slowing from >20% at the beginning of the year to 8-10%. Auto accident rates, unlikely to remain at -4%, aren't helping. Translation? Price increases are cooling.
GEICO is back. After a five-year reorganization, the Berkshire-owned insurer is firing on all cylinders, with solid profits and an expanding growth trajectory. BMO notes that GEICO's historically low advertising spending allowed PGR to win 1.5-2.0 million more customers in 2024 than it otherwise would have. But now, GEICO's rebuilt engine and industry-leading low expense ratio could recapture lost ground. Meanwhile, PGR's dominance in Florida (>21% market share) boosted EPS (+5%), but BMO warns that the combined ratio may begin to deteriorate. It's time to brace for reality.
Abercrombie & Fitch
What happened? On Thursday, BTIG initiated coverage of Abercrombie & Fitch Company with a "Buy" rating and a $120 price target.
Brief summary: A&F faces challenges, but growth is possible. Hollister's potential and cheap valuation are key drivers. Full story: BTIG puts Abercrombie & Fitch in the spotlight, noting that the stock is at a crossroads after two years of double-digit growth led by A&F. Of course, consumers are picky and comparisons are difficult, but the firm is betting that traffic and the health of the A&F brand can weather the storm. With headwinds from AUR—a factor within the company's control—easing, BTIG sees a return to growth. Meanwhile, Hollister is preparing to follow A&F's strategy, and international growth offers untapped potential.
Valuation? dirt cheap; BTIG argues that significant revenue declines are already priced in. The firm assigns a Buy rating with a $120 price target, calling the risk/reward attractive. In short: A&F isn't dead yet, and Hollister has room to grow.
Tesla
What happened? On Friday, Baird upgraded Tesla Inc to Overweight with a $548 price target. Brief: Baird upgrades Tesla based on Musk's compensation. Ambitious targets, bold model, high stakes.
Full story: Baird upgrades Tesla to Outperform, because why not? The team is rolling out a shiny new "compensation package" model because Musk's $46 billion payout apparently needs even more quantification. After a series of mediocre quarters and muted stock reactions, Baird is betting that the market is finally looking past the chaos to Tesla's future—or at least the illusory metrics built into Musk's compensation plan.
The proposed package is built on ambitious targets—think product launches and sharp market cap growth. Baird is here to lay it all out, modeling each hypothetical milestone to outline the "possibility." Spoiler: it's either brilliant valuation theater or the mother of all overpromises. In any case, buckle up – Tesla isn't just about cars anymore.